Advances in antiplatelet therapy in coronary artery disease: Importance of the platelet GPIIb/IIIa receptor

Journal of Interventional Cardiology

Volumn 10, Issue 5, 1997, Pages 327-333

  Timmis, Gerald C ^a   Khurana, Sandeep ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; CYCLOPEPTIDE; DISINTEGRIN; DMB 754; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; ORBOFIBAN; PLACEBO; RIDOGREL; RO 483657; THROMBOCYTE RECEPTOR; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN; XEMILOFIBAN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030728315     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.1997.tb00050.x     Document Type: Review

References (29)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet 1988; 2:349-360.
2. Ferneres J, Cambou J-P, Ruidavets J-B, et al. Trends in acute myocardial infarction prognosis and treatment in Southwestem France between 1985 and 1990 (The MONICA ProjectToulouse). Am J Cardiol 1995;75:1202-1205.
3. Ellerbeck EF, Jencks SF, Radford MI, et al. Quality of care for Medicare patients with acute myocardial infarction. A fourstate pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-1514.
4. Col NF, Yarzebski J, Gore JM, et al. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med 1995;155:1386-1389.
5. Garcia-Dorado D, Theroux P, Tornos P, et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischémie syndromes. Circulation 1995;92:1743-1748.
6. Meijer A, Verheugt FWA, Werter CIPJ, et al. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebocontrolled angiographie study. Results of the APRICOT Study. Circulation 1993;87:1524-1530.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830.
8. O'Connor CM, Fisher M, O'Gara, et al. The importance of aspirin dose in the protection of non-hemorrhagic stroke following acute myocardial infarction: Insights from the Coumadin Aspirin Reinfarction Study (CARS). Circulation 1996;94(SupplI):I-80.
9. Haynes RB, Sandier RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992;152:1376-1380.
10. The RAPT Investigators. Randomized trial of Ridogrel, a combined thromboxane Aa/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994;89:588-595.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
12. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
13. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IHa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
14. Topol EJ, Califf RM, Weisman HF, et al. on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343:881-886.
15. Lincoff AM, Tcheng JE, Califf RM, et al. for the PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein Ilb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997; 79:286-291.
16. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997:349:1429-1435.
17. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/iria receptor antagonist. Circulation 1994;89:3-12.
18. Mousa SA, DeGrado WF, Mu D-X, et al. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa Antagonist. Circulation 1996;93:537-543.
19. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein Ilb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-1559.
20. Théroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein Ilb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1997;94:899-905.
21. King SB HI. The RESTORE trial. Presented at the Intervent '97 (Interventional Cardiology and Pharmacology at the Crossroads Symposium), New Orleans, LA, November 10,1996.
22. Califf RM. The Lamifiban trials in acute myocardial infarction. Presented at the 12th International Workshop (Thrombolysis and Interventional Therapy in Acute Myocardial Infarction), New Orleans, LA, November 9, 1996.
23. Molitemo D. PARAGON (Lamifiban) results. Presented at the Intervent '97 (Interventional Cardiology and Pharmacology at the Crossroads Symposium), New Orleans, LA, November 10, 1996.
24. Tcheng JE, Ellis S, Kleiman NS, et al. Outcome of patients treated with the GPIIb/IIIa inhibitor Integrelin during coronary angioplasty: Results of the IMPACT study. Circulation 1993;88(Part 2):I-595.
25. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of Integrelin, a platelet glycoprotein Ilb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94:2083-2089.
26. The IMPACT-II Investigators. Randomised placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
27. Topol EJ. Rationale for abciximab and platelet glycoprotein Ilb/IIIa inhibitors in acute myocardial infarction. Presented at the 12th International Workshop (Thrombolysis and Interventional Therapy in Acute Myocardial Infarction), New Orleans, LA, November 9,1996.
28. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO lib) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621-1628.
29. Cannon CP. TIMI-12: Oral Ilb/IIIa inhibition in 300 patients after acute coronary syndromes. Presented at the 12th International Workshop (Thrombolysis and Interventional Therapy in Acute Myocardial Infarction), New Orleans, LA, November 9, 1996.